Investors bought shares of Johnson & Johnson (NYSE:JNJ) on weakness during trading hours on Friday. $178.45 million flowed into the stock on the tick-up and $65.26 million flowed out of the stock on the tick-down, for a money net flow of $113.19 million into the stock. Of all companies tracked, Johnson & Johnson had the highest net in-flow for the day. Johnson & Johnson traded down ($0.55) for the day and closed at $123.22

JNJ has been the topic of several research analyst reports. Standpoint Research initiated coverage on shares of Johnson & Johnson in a research note on Friday, May 20th. They set a “sell” rating and a $94.00 price target on the stock. Leerink Swann reissued an “outperform” rating and set a $140.00 price target (up from $125.00) on shares of Johnson & Johnson in a research note on Wednesday, July 20th. Argus increased their price target on shares of Johnson & Johnson from $116.00 to $130.00 and gave the company a “buy” rating in a research note on Wednesday, April 20th. BTIG Research reissued a “neutral” rating on shares of Johnson & Johnson in a research note on Friday, June 3rd. Finally, RBC Capital Markets reissued an “outperform” rating and set a $133.00 price target (up from $125.00) on shares of Johnson & Johnson in a research note on Wednesday, July 20th. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eleven have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $119.30.

The firm has a market cap of $337.11 billion and a PE ratio of 22.96. The stock’s 50 day moving average is $123.01 and its 200 day moving average is $113.08.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, July 19th. The company reported $1.74 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.68 by $0.06. The business had revenue of $18.50 billion for the quarter, compared to the consensus estimate of $17.98 billion. Equities research analysts anticipate that Johnson & Johnson will post $6.69 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 19th. Shareholders of record on Friday, August 5th will be issued a dividend of $0.29 per share. This represents a $1.16 dividend on an annualized basis and a yield of 0.94%.

In other news, VP Gary J. Pruden sold 9,735 shares of the company’s stock in a transaction on Tuesday, June 7th. The shares were sold at an average price of $116.03, for a total value of $1,129,552.05. Following the sale, the vice president now directly owns 43,630 shares of the company’s stock, valued at approximately $5,062,388.90. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, VP Dominic J. Caruso sold 41,146 shares of the company’s stock in a transaction on Tuesday, July 26th. The shares were sold at an average price of $125.01, for a total transaction of $5,143,661.46. Following the completion of the sale, the vice president now directly owns 157,819 shares in the company, valued at $19,728,953.19. The disclosure for this sale can be found here.

Several large investors have recently bought and sold shares of JNJ. Heritage Wealth Advisors raised its stake in Johnson & Johnson by 3.3% in the fourth quarter. Heritage Wealth Advisors now owns 9,944 shares of the company’s stock worth $1,021,000 after buying an additional 317 shares in the last quarter. Lourd Capital LLC raised its stake in Johnson & Johnson by 8.3% in the fourth quarter. Lourd Capital LLC now owns 11,115 shares of the company’s stock worth $1,142,000 after buying an additional 851 shares in the last quarter. Eidelman Virant Capital raised its stake in Johnson & Johnson by 11.8% in the fourth quarter. Eidelman Virant Capital now owns 11,623 shares of the company’s stock worth $1,193,000 after buying an additional 1,231 shares in the last quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC raised its stake in Johnson & Johnson by 9.9% in the fourth quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 13,032 shares of the company’s stock worth $1,339,000 after buying an additional 1,179 shares in the last quarter. Finally, Private Capital Management Inc. purchased a new stake in Johnson & Johnson during the fourth quarter worth approximately $1,428,000.

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.